All News #Library
Biotech
Accutar Receives FDA Fast Track Designation For AC699 In ER+/HER2- Breast Cancer
14 Aug 2024 //
BUSINESSWIRE
Evommune and Accutar Biotechnology Announce AI Drug Discovery Collaboration
28 Nov 2023 //
PR NEWSWIRE
Accutar Announces First Patient Dosed with AC0676 in Phase 1 Study
20 Jun 2023 //
BUSINESSWIRE
Accutar Announces First Patient Dosed in China with AC0176 in Phase 1 Study
23 Feb 2023 //
BUSINESSWIRE
Accutar Announces FDA Clearance of IND Application for Phase 1 Trial of AC0676
03 Feb 2023 //
BUSINESSWIRE

Market Place
Sourcing Support